The Aging Animal Models and Longevity Assessment Core published the first study to demonstrate that long-term oral, daily dosing with the anti-aging drug, rapamycin, is well tolerated in a non-human primate and modulates mTOR signaling. The ability to rapidly and reliably dose socially housed marmosets with an oral form of rapamycin that is well tolerated […]
read moreA research group at Southwest Research Institute was interested in testing whether α-linoleic acid (ALA) had effects on aging based upon their experiments showing […]
read moreThe statistical component of the administration core is lead by Dr. Jonathan Gelfond and has contributed to multi-institutional collaborations and has projected its capability to the aging research community through analytical tools.
read moreThe important and significant discovery in 2009 that the drug rapamycin extended longevity in a mammal (BL6 mice) and that drugs can be used to study mechanisms of aging has required the development of early stage research design procedures to[…]
read moreDr. Rochelle Buffenstein of the Aging Animal Models and Longevity Assessment Core and her team have continued to examine various aspects of age-related changes in physiology in the naked mole-rat and within the past 5 years have discovered some significant breakthroughs.
read moreThe Research Development Core would like to congratulate our 2014-2015 Pilot Grant Awardees! Martin Paukert, M.D. and Pei Wang, Ph.D. have been selected to receive Pilot Grants from the San Antonio Nathan Shock Center Research Development Core.
read more